Addiction Treatment
23 articles on Addiction Treatment, researched and written by the Shotlee Editorial Team from primary sources.
Fat Jabs Slash Alcohol-Related Hospitalisations by More Than a Quarter
Recent analysis indicates that GLP-1 weight loss medications significantly reduce the risk of alcohol-related hospital admissions by approximately 26 percent compared to other diabetes treatments.
8 min read
Oral GLP-1 Drugs May Quiet the Brain's Food Craving Circuit
New research suggests that oral GLP-1 medications, including those used for weight loss and diabetes, might work by influencing the brain's reward pathways, potentially reducing cravings for enjoyable foods and offering insights into treating substance use disorders.
8 min read
GLP-1 Weight-Loss Drugs Linked to Lower Risks of Addiction and Overdose
Explore the groundbreaking research linking GLP-1 medications, including Ozempic, Wegovy, Mounjaro, and Zepbound, to a reduced risk of substance use disorders and fewer addiction-related emergencies.
8 min read
Beyond Weight Loss: The Expanding Horizon of GLP-1 Therapies
GLP-1 agonists, famously known for Ozempic and Wegovy, are making waves beyond their initial indications. While weight loss and diabetes management remain key, researchers are uncovering a broader therapeutic potential for these powerful peptide therapies.
8 min read
Beyond Appetite: How GLP-1 Drugs May Be Rewiring the Human Brain
GLP-1 receptor agonists, initially celebrated for revolutionizing diabetes and weight management, are now at the center of an unplanned, massive neuroscience experiment. Emerging data suggests these powerful medications are doing more than just regulating metabolism; they appear to be structurally and functionally altering key brain systems.
7 min read
GLP-1 Drugs: A New Frontier in Addiction Treatment?
Could the same medications revolutionizing weight loss and diabetes management also hold the key to treating addiction? Emerging research suggests GLP-1 receptor agonists may play a significant role.
8 min read
GLP-1 Drugs for Alcohol Use Disorder: The Future of Addiction Treatment?
GLP-1 receptor agonists, widely known for their efficacy in weight management and type 2 diabetes, are showing remarkable promise in addressing Alcohol Use Disorder (AUD). Emerging research suggests these injectable therapies may fundamentally alter the brain's reward pathways, offering a novel pharmaceutical path for those struggling with heavy drinking.
6 min read
What Happens to Your Body When You Take a GLP-1 Medication?
GLP-1 medications like Ozempic and Wegovy have transformed weight loss. But what exactly happens inside your body? We break down the science, mechanisms, and sustainability of peptide therapy.
8 min read
Grim Effects of Stopping GLP-1s Like Ozempic, Study Finds
New research paints a stark picture: stopping GLP-1 drugs like Ozempic can rapidly reverse cardiovascular benefits, with risks spiking 8% after just six months. Published in BMJ Medicine, the study tracked over 333,000 adults and warns of 'metabolic whiplash.' Patients face weight regain, inflammation resurgence, and lasting scars from interruptions.
4 min read
Ozempic Cuts Depression, Anxiety, and Addiction Risk: Study
A groundbreaking study reveals that Ozempic and other GLP-1 medications like semaglutide significantly lower risks of depression, anxiety, addiction, and even suicidal behavior. Analyzing nearly 100,000 people, researchers found up to 47% reductions in related hospital visits and work absences. This could transform treatment for those with overlapping metabolic and mental health issues.
5 min read
Ozempic Turned Happy Drunk to Sad One with Horrendous Hangovers
Trey Luker-Stewart lost 60 pounds on Ozempic, but it transformed his drinking from fun nights to anxious, emotional ones with brutal hangovers. As a Dallas bar owner, he's seen a 35% drop in alcohol sales linked to GLP-1 drugs. Doctors reveal why these medications blunt alcohol's rewards and worsen next-day effects.
5 min read
Ozempic-Like Shots Curb 'Drug Noise' for Addicts: Insurance When?
GLP-1 drugs like Ozempic are silencing 'drug noise' in addicts, slashing overdoses and ER visits per a massive veterans study. Dr. Ziyad Al-Aly explains how these shots target brain reward systems. But FDA approval and insurance coverage remain years away—here's what patients need to know.
5 min read
GLP-1s Reduce Substance Addiction Risk in US Veterans: BMJ Study
An observational study in the British Medical Journal reveals GLP-1 medications like semaglutide significantly lower substance use disorder (SUD) risk in US veterans with type 2 diabetes. Compared to SGLT2 inhibitors, GLP-1s reduced new addiction risks by up to 25% and improved outcomes like 50% fewer substance-related deaths. These findings challenge traditional views on addiction and metabolic health.
5 min read
Study: GLP-1s Reduce Addiction Risks Beyond Weight Loss
A groundbreaking study in the British Medical Journal reveals that GLP-1 drugs like Ozempic offer benefits far beyond weight loss and diabetes control—they significantly reduce risks of alcohol, tobacco, cannabis, and cocaine abuse. Among 606,434 US veterans with type 2 diabetes, these medications lowered substance abuse risks by up to 20%. Experts caution that while promising, more research is needed.
5 min read
Study: GLP-1 Drugs May Fight Addiction Across Major Substances
Patients on GLP-1 drugs like Ozempic report losing interest in cigarettes, alcohol, and more without effort. A physician-led study of over 600,000 VA patients reveals these medications cut addiction-related deaths by 50% and prevent new substance use disorders. This could transform treatment for alcohol, opioids, cocaine, cannabis, and nicotine.
5 min read
Ozempic May Lower Addiction Risk, New BMJ Study Shows
A groundbreaking BMJ study reveals GLP-1 drugs like Ozempic may reduce the risk of developing substance use disorders by 14% in diabetes patients. Among those with existing addictions, hospital admissions dropped 26%. While promising, these are associations from veteran health records—randomized trials are needed for proof.
5 min read
How GLP-1s Helped a Rhode Island Mom Get Sober After Alcoholism
A Rhode Island mother battled alcoholism for years, losing custody of her son, until GLP-1 drugs like Wegovy and Mounjaro helped curb her cravings in a pilot program. Gina Roberts shares her journey to two years sober, her own apartment, and family reunion. Addiction specialist Dr. Steven Klein discusses the promising role of these medications alongside traditional supports.
6 min read
GLP-1s Curb Cravings Beyond Food: 600K Study Suggests
Patients on GLP-1 drugs report losing cravings not just for food, but for cigarettes, alcohol, and more—without effort. A new study of over 600,000 people confirms dramatic reductions in overdoses, deaths, and new addictions. Could semaglutide and tirzepatide redefine addiction care?
5 min read
How GLP-1s Helped a Rhode Island Mom Get Sober After Alcoholism
A Rhode Island mother battled alcoholism for years, losing custody of her son—until GLP-1 drugs like Wegovy changed everything. In a pilot program at Open Doors transitional home, Gina Roberts stopped her cravings, got sober for two years, and rebuilt her life. Addiction specialists share why these weight-loss meds show promise for addiction recovery.
5 min read
Tirzepatide in Mounjaro Cuts Alcohol Intake Over 50%, Study Shows
The weight-loss drug Mounjaro's active ingredient, tirzepatide, is showing promise beyond metabolic health by slashing alcohol intake in animal models. A new study from the University of Gothenburg found it reduced voluntary consumption by over 50%, curbed binge drinking, and prevented relapse. This could signal a new avenue for treating alcohol use disorder through GLP-1/GIP receptor agonism.
6 min read
Can Ozempic Be Used for Addiction Treatment?
The idea that Ozempic could treat addictions is gaining traction online, but it's crucial to examine the scientific basis for these claims. While some studies explore its impact on reward mechanisms, the drug's effects on the brain are not fully understood.
3 min read
Could This Be the 'Ozempic of Alcohol'? Existing Medication Shows Promise
An affordable and readily accessible medication is gaining attention as a potential solution for curbing alcohol cravings, drawing comparisons to the way GLP-1 drugs manage food cravings. Naltrexone, by impacting dopamine-reward pathways, reduces the satisfying feeling associated with alcohol consumption, thus diminishing the desire for it. Research and anecdotal evidence suggest it could be a game-changer for many.
3 min read
GLP-1 Drugs: New Hope for Weight Loss and Addiction Treatment?
Emerging research suggests that GLP-1 drugs, originally developed for diabetes and weight loss, may also be effective in treating alcohol and drug addiction. This blog explores the science and potential of these groundbreaking treatments.
4 min read